LMS Delivers CALM CIS 3.08 to Marketplace

Click here for the PDF version of this release
Back to LMS News

Montreal, Quebec, October 2, 2007 – LMS Medical Systems Inc.,, a healthcare technology company and developer of the CALM® patient safety tools for obstetrics, today announced the general availability of the latest release of its clinical information system, CALM 3.08.

Designed with patient safety in mind, CALM 3.08 includes enhanced components to streamline charting and reporting, thus reducing administrative tasks to allow clinicians more time at the bedside with laboring mothers.

According to Diane Côté, President and CEO of LMS, “CALM offers a significant contribution to quality patient care in obstetrics. This latest version continues to support consistent communication among clinical team members.”

LMS’ CALM software combines advanced surveillance, archival, and maternal-fetal charting with unique risk management tools enabling personalized labor monitoring, fetal heart rate pattern recognition, and prenatal assessment of the risk of shoulder dystocia with injury. Used in hospitals throughout North America, CALM modules can also be purchased by physician clinics as well as insurers who offer risk prevention solutions.

ABOUT LMS
LMS is a leader in the application of advanced mathematical modeling and neural networks for medical use. The LMS CALM Suite™ provides physicians, nursing staff, risk managers and hospital administrators with clinical information systems and risk management tools designed to improve outcomes and patient care for mothers and their infants during labor and delivery.

Except for historical information contained herein, the matters discussed in this news release are forward-looking statements. Because these forward looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed implied by the forward-looking statements including, but without limitation, economic conditions in general and in the healthcare market, the demand for and market for our products in domestic and international markets, our current dependence on the CALM product suite, the challenges associated with developing new products and obtaining regulatory approvals if necessary, research and development activities, the uncertainty of acceptance of our products by the medical community, the lengthy sales cycle for our products, third party reimbursement, competition in our markets, including the potential introduction of competitive products by others, our dependence on our distributors, physician training, enforceability and the costs of enforcement of our patents, potential infringements of our patents and the other factors set forth from time to time in the Company's filings with the United States Securities and Exchange Commission and with the Canadian Securities Commissions. The Company has no intention of or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.